Management of drug interactions with direct‐acting antivirals in Dutch HIV/hepatitis C virus‐coinfected patients: adequate but not perfect. Issue 3 (1st December 2017)

• Record Type: Journal Article
• Authors: Smolders, EJ; Smit, C; de Kanter, CTMM; Dofferhoff, ASM; Arends, JE; Brinkman, K; Rijnders, B; van der Valk, M; Reiss, P; Burger, DM
• Other Names: Prins J. M. investigator.; Kuijpers T. W. investigator.; Scherpbier H. J. investigator.; van der Meer J. T. M. investigator.; Wit F. W. M. N. investigator.; Godfried M. H. investigator.; van der Poll T. investigator.; Nellen F. J. B. investigator.; Geerlings S. E. investigator.; van Vugt M. investigator.; Pajkrt D. investigator.; Wiersinga W. J. investigator.; Goorhuis A. investigator.; Hovius J. W. investigator.; Bijsterveld M. A. H. investigator.; van Eden J. investigator.; van Hes A. M. H. investigator.; Mutschelknauss M. investigator.; Nobel H. E. investigator.; Pijnappel F. J. J. investigator.; Weijsenfeld A. M. investigator.; Jurriaans S. investigator.; Back N. K. T. investigator.; Zaaijer H. L. investigator.; Berkhout B. investigator.; Cornelissen M. T. E. investigator.; Schinkel C. J. investigator.; Thomas X. V. investigator.; De Ruyter Ziekenhuis Admiraal investigator.; van den Berge M. investigator.; Stegeman A. investigator.; Baas S. investigator.; Hage de Looff L. investigator.; Wintermans B. investigator.; Veenemans J. investigator.; Ziekenhuis Catharina investigator.; Pronk M. J. H. investigator.; Ammerlaan H. S. M. investigator.; de Munnik E. S. investigator.; van Beek E. investigator.; Jansz A. R. investigator.; Tjhie J. investigator.; Wegdam M. C. A. investigator.; Deiman B. investigator.; Scharnhorst V. investigator.; Ziekenhuis Elisabeth‐TweeSteden investigator.; van Kasteren M. E. E. investigator.; Brouwer A. E. investigator.; van Erve R. investigator.; de Kruijf‐van de Wiel B. A. F. M. investigator.; Keelan‐Pfaf S. investigator.; van der Ven B. investigator.; Buiting A. G. M. investigator.; Kabel P. J. investigator.; Versteeg D. investigator.; Kinderziekenhuis Emma investigator.; van der Plas A. investigator.; van der Ende M. E. investigator.; Bax H. I. investigator.; van Gorp E. C. M. investigator.; Nouwen J. L. investigator.; Schurink C. A. M. investigator.; Verbon A. investigator.; de Vries‐Sluijs T. E. M. S. investigator.; Bassant N. investigator.; van Beek J. E. A. investigator.; Vriesde M. investigator.; van Zonneveld L. M. investigator.; van den Berg‐Cameron H. J. investigator.; Bruinsma‐Broekman F. B. investigator.; de Groot J. investigator.; de Zeeuw‐de Man M. investigator.; Boucher C. A. B. investigator.; Koopmans M. P. G. investigator.; van Kampen J. J. A. investigator.; Pas S. D. investigator.; Driessen G. J. A. investigator.; van Rossum A. M. C. investigator.; van der Knaap L. C. investigator.; Visser E. investigator.; Branger J. investigator.; Rijkeboer‐Mes A. investigator.; Duijf‐van de Ven C. J. H. M. investigator.; Schippers E. F. investigator.; van Nieuwkoop C. investigator.; van IJperen J. M. investigator.; Geilings J. investigator.; van der Hut G. investigator.; Franck P. F. H. investigator.; van Eeden A. investigator.; Brokking W. investigator.; Groot M. investigator.; Elsenburg L. J. M. investigator.; Damen M. investigator.; Kwa I. S. investigator.; Groeneveld P. H. P. investigator.; Bouwhuis J. W. investigator.; van den Berg J. F. investigator.; van Hulzen A. G. W. investigator.; van der Bliek G. L. investigator.; Bor P. C. J. investigator.; Bloembergen P. investigator.; Wolfhagen M. J. H. M. investigator.; Ruijs G. J. H. M. investigator.; Kroon F. P. investigator.; de Boer M. G. J. investigator.; Jolink H. investigator.; Vollaard A. M. investigator.; Dorama W. investigator.; van Holten N. investigator.; Claas E. C. J. investigator.; Wessels E. investigator.; den Hollander J. G. investigator.; Pogany K. investigator.; Roukens A. investigator.; Kastelijns M. investigator.; Smit J. V. investigator.; Smit E. investigator.; Struik‐Kalkman D. investigator.; Tearno C. investigator.; Bezemer M. investigator.; van Niekerk T. investigator.; Pontesilli O. investigator.; Lowe S. H. investigator.; Oude Lashof A. M. L. investigator.; Posthouwer D. investigator.; Ackens R. P. investigator.; Schippers J. investigator.; Vergoossen R. investigator.; Weijenberg‐Maes B. investigator.; van Loo I. H. M. investigator.; Havenith T. R. A. investigator.; Leyten E. M. S. investigator.; Gelinck L. B. S. investigator.; van Hartingsveld A. Y. investigator.; Meerkerk C. investigator.; Wildenbeest G. S. investigator.; Mutsaers J. A. E. M. investigator.; van Veen S. Q. investigator.; Slotervaart MC investigator.; Mulder J. W. investigator.; Vrouenraets S. M. E. investigator.; Lauw F. N. investigator.; van Broekhuizen M. C. investigator.; Paap H. investigator.; Vlasblom D. J. investigator.; Smits P. H. M. investigator.; Zuiderzee MC investigator.; Weijer S. investigator.; El Moussaoui R. investigator.; Bosma A. S. investigator.; van Vonderen M. G. A. investigator.; van Houte D. P. F. investigator.; Kampschreur L. M. investigator.; Dijkstra K. investigator.; Faber S. investigator.; Weel J. investigator.; Kootstra G. J. investigator.; Delsing C. E. investigator.; van der Burg‐van de Plas M. investigator.; Heins H. investigator.; Lucas E. investigator.; Kortmann W. investigator.; van Twillert G. investigator.; Cohen Stuart J. W. T. investigator.; Diederen B. M. W. investigator.; Renckens R. investigator.; Ruiter‐Pronk D. investigator.; van Truijen‐Oud F. A. investigator.; van der Reijden W. A. investigator.; Jansen R. investigator.; van den Berk G. E. L. investigator.; Blok W. L. investigator.; Frissen P. H. J. investigator.; Lettinga K. D. investigator.; Schouten W. E. M. investigator.; Veenstra J. investigator.; Brouwer C. J. investigator.; Geerders G. F. investigator.; Hoeksema K. investigator.; Kleene M. J. investigator.; van der Meché I. B. investigator.; Spelbrink M. investigator.; Sulman H. investigator.; Toonen A. J. M. investigator.; Wijnands S. investigator.; Kwa D. investigator.; Witte E. investigator.; van Crevel R. investigator.; Keuter M. investigator.; van der Ven A. J. A. M. investigator.; ter Hofstede H. J. M. investigator.; Albers M. investigator.; Grintjes‐Huisman K. J. T. investigator.; Marneef M. investigator.; Hairwassers A. investigator.; Rahamat‐Langendoen J. investigator.; Burger D. investigator.; Gisolf E. H. investigator.; Hassing R. J. investigator.; Claassen M. investigator.; ter Beest G. investigator.; van Bentum P. H. M. investigator.; Langebeek N. investigator.; Tiemessen R. investigator.; Swanink C. M. A. investigator.; van Lelyveld S. F. L. investigator.; Soetekouw R. investigator.; van der Prijt L. M. M. investigator.; van der Swaluw J. investigator.; Bermon N. investigator.; Herpers B. L. investigator.; Veenendaal D. investigator.; Verhagen D. W. M. investigator.; van Wijk M. investigator.; Bierman W. F. W. investigator.; Bakker M. investigator.; Kleinnijenhuis J. investigator.; Kloeze E. investigator.; Scholvinck H. investigator.; Stienstra Y. investigator.; Vermont C. L. investigator.; Wilting K. R. investigator.; Boonstra A. investigator.; de Groot‐de Jonge H. investigator.; van der Meulen P. A. investigator.; de Weerd D. A. investigator.; Niesters H. G. M. investigator.; van Leer‐Buter C. C. investigator.; Knoester M. investigator.; Hoepelman A. I. M. investigator.; Barth R. E. investigator.; Bruns A. H. W. investigator.; Ellerbroek P. M. investigator.; Mudrikova T. investigator.; Oosterheert J. J. investigator.; Schadd E. M. investigator.; Wassenberg M. W. M. investigator.; van Zoelen M. A. D. investigator.; Aarsman K. investigator.; van Elst‐Laurijssen D. H. M. investigator.; van Oers‐Hazelzet E. E. B. investigator.; van Berkel M. investigator.; Schuurman R. investigator.; Verduyn‐Lunel F. investigator.; Wensing A. M. J. investigator.; Peters E. J. G. investigator.; van Agtmael M. A. investigator.; Bomers M. investigator.; de Vocht J. investigator.; Heitmuller M. investigator.; Laan L. M. investigator.; Ang C. W. investigator.; van Houdt R. investigator.; Pettersson A. M. investigator.; Vandenbroucke‐Grauls C. M. J. E. investigator.; Geelen S. P. M. investigator.; Wolfs T. F. W. investigator.; Bont L. J. investigator.; Nauta N. investigator.; Bezemer D. O. investigator.; van Sighem A. I. investigator.; Boender T. S. investigator.; Zaheri S. investigator.; Hillebregt M. investigator.; de Jong A. investigator.; Bergsma D. investigator.; de Lang A. investigator.; Grivell S. investigator.; Jansen A. investigator.; Rademaker M. J. investigator.; Raethke M. investigator.; Meijering R. investigator.; Schnörr S. investigator.; de Groot L. investigator.; van den Akker M. investigator.; Bakker Y. investigator.; Claessen E. investigator.; El Berkaoui A. investigator.; Koops J. investigator.; Kruijne E. investigator.; Lodewijk C. investigator.; Munjishvili L. investigator.; Peeck B. investigator.; Ree C. investigator.; Regtop R. investigator.; Ruijs Y. investigator.; Rutkens T. investigator.; van de Sande L. investigator.; Schoorl M. investigator.; Timmerman A. investigator.; Tuijn E. investigator.; Veenenberg L. investigator.; van der Vliet S. investigator.; Wisse A. investigator.; Woudstra T. investigator.; Tuk B. investigator.;
• Is Part Of: HIV medicine. Volume 19:Issue 3(2018)
• Page Start: 216
• Page End: 226
• Publication Date: 2017-12-01
• Subjects: combination antiretroviral therapy -- co‐medication -- direct‐acting antivirals -- drug–drug interactions -- hepatitis C -- HIV; HIV infections -- Treatment -- Periodicals; HIV-positive persons -- Periodicals; HIV infections -- Treatment -- Decision making -- Periodicals; 616.9792
• DOI: 10.1111/hiv.12570
• Languages: English
• ISSNs: 1464-2662

Abstract

Abstract : Objectives: Direct‐acting antivirals (DAAs) for treatment of chronic hepatitis C virus (HCV) infection can cause drug–drug interactions (DDIs) with combination antiretroviral therapy (cART) and non‐cART co‐medication. We mapped how physicians manage DDIs between DAAs and co‐medication and analysed treatment outcomes. Methods: Data were prospectively collected as part of the ATHENA HIV observational cohort and retrospectively analysed. Dutch patients with HIV/HCV coinfection who initiated treatment with DAAs between January 2015 and May 2016 were included. Co‐medication 3 months prior to and during DAA therapy was identified. Potential DDIs with the DAAs were checked usinghttp://hep-druginteractions.org . DDIs were categorized as: (1) no interaction expected; (2) potential interaction; (3) contra‐indication; (4) no recommendation. These categories were used to determine which patients switched or had a DDI during DAA therapy with co‐medication. Results: A total of 423 patients were treated with DAAs, of whom 418 (99%) used cART and 251 (59%) used non‐cART co‐medication. Before commencing DAA treatment, in 17 of 84 (20%) patients the non‐cART co‐medication which could result in a category 2/3 DDI was discontinued before DAA initiation, including two of six (33%) prescriptions of category 3 drugs. A total of 196 of 418 (47%) patients had a category 2/3 DDI between their DAA regimen and cART. Category 2/3 DDIs were prevented by switching cART in 78 of 147 (53%) and 47 of 49 (98%) patients. Overall, 367 of 423 (87%) patients have achieved a sustained virological response (33 in follow‐up). Conclusions: Prescription patterns suggest that physicians are aware of potential DDIs between co‐medication and DAAs, in particular potential DDIs with cART. Greater awareness is needed concerning category 3 interactions between non‐cART co‐medication and DAAs.